178 related articles for article (PubMed ID: 37314661)
1. Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models.
Franklin M; Hernández Alava M
Qual Life Res; 2023 Oct; 32(10):2763-2778. PubMed ID: 37314661
[TBL] [Abstract][Full Text] [Related]
2. Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness.
Franklin M; Enrique A; Palacios J; Richards D
Qual Life Res; 2021 Sep; 30(9):2633-2647. PubMed ID: 33835414
[TBL] [Abstract][Full Text] [Related]
3. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
4. Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation.
Mukuria C; Franklin M; Hinde S
Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38664317
[TBL] [Abstract][Full Text] [Related]
5. Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A.
Xu RH; Keetharuth AD; Wang LL; Cheung AW; Wong EL
Eur J Health Econ; 2022 Mar; 23(2):165-176. PubMed ID: 34338898
[TBL] [Abstract][Full Text] [Related]
6. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data.
Neilson AR; Jones GT; Macfarlane GJ; Pathan EM; McNamee P
Eur J Health Econ; 2022 Nov; 23(8):1357-1369. PubMed ID: 35113270
[TBL] [Abstract][Full Text] [Related]
7. Mapping Short Warwick and Edinburgh Mental Wellbeing Scale (SWEMWBS) to Recovering Quality of Life (ReQoL) to estimate health utilities.
Keetharuth AD; Gray LA; McGrane E; Worboys H; Orozco-Leal G
Health Qual Life Outcomes; 2024 Jan; 22(1):7. PubMed ID: 38221610
[TBL] [Abstract][Full Text] [Related]
8. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
[TBL] [Abstract][Full Text] [Related]
9. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures.
Brazier J; Connell J; Papaioannou D; Mukuria C; Mulhern B; Peasgood T; Jones ML; Paisley S; O'Cathain A; Barkham M; Knapp M; Byford S; Gilbody S; Parry G
Health Technol Assess; 2014 May; 18(34):vii-viii, xiii-xxv, 1-188. PubMed ID: 24857402
[TBL] [Abstract][Full Text] [Related]
10. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
11. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
[TBL] [Abstract][Full Text] [Related]
12. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma.
Gray LA; Hernández Alava M; Wailoo AJ
Value Health; 2018 Jun; 21(6):748-757. PubMed ID: 29909881
[TBL] [Abstract][Full Text] [Related]
13. A (five-)level playing field for mental health conditions?: exploratory analysis of EQ-5D-5L-derived utility values.
Camacho EM; Shields G; Lovell K; Coventry PA; Morrison AP; Davies LM
Qual Life Res; 2018 Mar; 27(3):717-724. PubMed ID: 29248995
[TBL] [Abstract][Full Text] [Related]
14. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
15. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis.
Yang F; Wong CKH; Luo N; Piercy J; Moon R; Jackson J
Eur J Health Econ; 2019 Nov; 20(8):1195-1206. PubMed ID: 31338698
[TBL] [Abstract][Full Text] [Related]
16. The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome.
Sturkenboom R; Keszthelyi D; Brandts L; Weerts ZZRM; Snijkers JTW; Masclee AAM; Essers BAB
Qual Life Res; 2022 Apr; 31(4):1209-1221. PubMed ID: 34546554
[TBL] [Abstract][Full Text] [Related]
17. Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial.
Pennington BM; Hernández-Alava M; Hykin P; Sivaprasad S; Flight L; Alshreef A; Brazier J
Value Health; 2020 Jul; 23(7):928-935. PubMed ID: 32762995
[TBL] [Abstract][Full Text] [Related]
18. Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease.
Steiner IM; Bokemeyer B; Stargardt T
Eur J Health Econ; 2024 Apr; 25(3):539-548. PubMed ID: 37368061
[TBL] [Abstract][Full Text] [Related]
19. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health.
Crick K; Al Sayah F; Ohinmaa A; Johnson JA
Qual Life Res; 2018 Jun; 27(6):1625-1633. PubMed ID: 29516342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
